Top

Published in:

01-12-2016 | Original Article

Double positivity of the IgG isotype of both anticardiolipin and anti-β2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data

Authors: Mirjana Bećarević, Duško Mirković, Svetlana Ignjatović

Published in: Clinical Rheumatology | Issue 12/2016

Abstract

Although numerous studies investigated the association between homocysteine (Hcy), tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP) and apolipoproteins (apo_s) with thrombosis and/or recurrent pregnancy losses, studies that analyzed the abovementioned parameters and multiple positivity of antiphospholipid antibodies (aPL Abs) in patients with primary antiphospholipid syndrome (PAPS) are lacking. Therefore, the aim of this study was to analyze the presence of various combinations of the abovementioned parameters and their associations with clinical and/or serological features of PAPS. High-pressure liquid chromatography (HPLC) was used for determination of Hcy, while apoAI, apoB, and lipoprotein (Lp) (a) concentrations were estimated by immunonephelometry. High-sensitivity C-reactive protein (hsCRP) was measured by immunoturbidimetry. Apo (a), TNF-α, and aPL Abs were measured by ELISA. Various combinations of analyzed parameters (Hcy/CRP/TNF/apoAI/apoB/apo (a)/Lp (a)) were not associated with a single presence of either aPL Abs. Double positivity for both isotypes of anticardiolipin (aCL) Abs (IgG + IgM) was associated with the increased apoB levels. The presence of the IgG isotype of both aCL + anti-beta2 glycoprotein I (aβ2gpI) Abs was associated with the highest number of analyzed parameters (i.e., increased levels of hsCRP, Lp (a), and apo (a)). The presence of the IgG isotype of both aCL + aβ2gpI Abs was associated with the highest number of vascular impairment parameters in patients with PAPS, and this combination confers the highest risk for the recurrence of thrombotic episodes. This is the first report that analyzed the association between various combinations of vascular impairment parameters with multiple aPL Ab positivity. Our results provide a rationale for further investigations of therapeutic approaches for PAPS patients.

Bertolaccini ML, Ammengual O, Andreolii L et al (2014) 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13:917–930CrossRefPubMed

Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295–306CrossRefPubMed

van den Hoogen LL, van Roon JAG, Radstake TRDJ et al (2015) Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun Rev. doi:10.1016/j.autrev.2015.08.011 PubMed

D’Ippolito S, Meroni PL, Koike T, Veglia M, Scambia G, Di Simone N (2014) Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun Rev 13:901–908CrossRefPubMed

Doring Y, Hurst J, Lorenz M et al (2010) Human antiphospholipid antibodies induce TNFa in monocytes via Toll-like receptor 8. Immunobiology 215:230–241CrossRefPubMed

Nandeesha H, Bobby Z, Selvaraj N et al (2015) Pre-hypertension: is it an inflammatory state? Clin Chim 451:338–342CrossRef

Popa C, Netea MG, van Riel PLCM et al (2007) The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48:751–762CrossRefPubMed

Ozturk ZG, Ekmekci H, Ekmecki OB et al (2010) Nontraditional risk factors in carotid artery disease. Clin Appl Thromb/Hemost 16(5):554–558CrossRef

Himerova J (2013) Homocysteine and venous thromboembolism—is there any link? Cor Et Vasa 55:E248–E258CrossRef

10.

Lee RM, Brown MA, Ward K, Nelson L, Branch DW, Silver RM (2004) Homocysteine levels in women with antiphospholipid syndrome and normal fertile controls. J Rep Immunol 63:23–30CrossRef

11.

Baraka E, El Dein M, Farouk H, Moutaz YE (2015) Hyperhomocysteinemia and metabolic syndrome are risk factors for sub-clinical atherosclerosis in women with systemic lupus erythematosus. Egypt Rheumatol 37:67–74CrossRef

12.

Papageorgiou N, Tousoulis D (2015) Interaction between HDL and inflammation: when the good turns to be bad. Int J Cardiol 189:15–17CrossRefPubMed

13.

Bećarević M, Andrejević S, Miljić P, Bonači-Nikolić B, Majkić-Singh N (2007) Serum lipids and anti-oxidized LDL antibodies in primary antiphospholipid syndrome. Clin Exp Rheumatol 25(3):361–366PubMed

14.

Bećarević M, Ignjatović S (2016) Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data. Clin Rheumatol. doi:10.1007/s10067-016-3345-3

15.

Brandt JT, Triplett DA, Alving B et al (1995) Criteria for the diagnosis of lupus anticoagulants: an update on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 74(4):1185–1190PubMed

16.

Just SA, Nybo M, Laustrup H, Jensen Hansen IM, Junker P, Just Vinholt P (2016) Single test isolated lupus anticoagulant positivity is associated with increased plasma levels of inflammatory markers and dyslipidemia. Lupus 25:241–247CrossRefPubMed

17.

Saraiva SS, Custodio IF, de Moraes Mazzeto B et al (2015) Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. Thromb Res 136:1174–1178CrossRef

18.

Kronenberg F (2014) Lipoprotein (a) in various conditions: to keep a sense of proportions. Atherosclerosis 234:249–251CrossRefPubMed

19.

Cugno M, Borghi MO, Lonati LM et al (2010) Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun 34:105–110CrossRefPubMed

20.

Olszanecka-Glinianowicz M, Chudek J, Kocelak P et al (2011) Body fat changes and activity of tumor necrosis factor a system-a 5-year follow-up study. Metab Clin Exp 60:531–536CrossRefPubMed

21.

Peluso I, Palmery M (2015) The relationship between body weight and inflammation: lesson from anti-TNFa antibody therapy. Human Immunol. doi:10.1016/j.humimm.2015.10.008

22.

Caldas CA, da Mota LMH, de Carvalho JF (2011) Obesity in primary antiphospholipid syndrome is associated with worse outcome. Joint Bone Spine 78:319–325CrossRef

23.

Miesbach W, Gokpinar B, Gilzinger A, Claus D, Scharrer I (2005) Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome. Immunobiology 210:755–760CrossRefPubMed

24.

Batuca JR, Ames PR, Amaral M et al (2009) Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 48(1):26–31CrossRef

25.

Svenungsson E, Fei GZ, Jensen-Urstad K et al (2003) TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 12:454–461CrossRefPubMed

Title: Double positivity of the IgG isotype of both anticardiolipin and anti-β2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data
Authors: Mirjana Bećarević
Duško Mirković
Svetlana Ignjatović
Publication date: 01-12-2016
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 12/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-016-3438-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Double positivity of the IgG isotype of both anticardiolipin and anti-β2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2016

Differentiating biosimilarity and comparability in biotherapeutics

A discrete choice experiment to explore patients’ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis

Musculoskeletal manifestations of primary hyperparathyroidism

The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis

Prediction of Antiphospholipid syndrome using Annexin A5 competition assay in patients with SLE

STAT4 rs7574865 G/T polymorphism is associated with rheumatoid arthritis and disease activity, but not with anti-CCP antibody levels in a Mexican population

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page